|
|
Post by Hot Christian Stocks on Mar 4, 2014 9:24:59 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 5, 2014 9:25:06 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 6, 2014 9:16:54 GMT -5
$PLPL Legalizing Medical Marijuana Gaining More Momentum in Mid-Term Election YearNEW YORK, NY -- (Marketwired) -- 03/06/14 Plandaí Biotechnology (OTCQB: PLPL) is one of a handful of publicly traded companies that are eagerly anticipating the legalization of medical marijuana nationwide. Currently the drug is legal medicinally in 20 states and Washington, D.C., but in this election year, that number is likely to grow. In each national election year, the frenzy begins again and with it, a growing momentum that has the U.S. drawing closer to a nationwide acceptance. Read More www.stockwatch.com/News/Item.aspx?bid=U-i1095827-U%3aPLPL-20140306&symbol=PLPL®ion=U
|
|
|
|
Post by Hot Christian Stocks on Mar 7, 2014 9:32:09 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 7, 2014 12:27:17 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 10, 2014 8:43:58 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 11, 2014 6:08:10 GMT -5
$PLPL pre-mkt News! Plandai Assumes Role in Legalizing Medical Marijuana in South Africa SEATTLE, WA(eTeligis.com)Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that it will assume a role in helping to craft legislation that is expected to result in the eventual legalization of marijuana for medical purposes in South Africa. Planda has retained the law firm Werksmans Attorneys, (LEX Africa) Sandton, South Africa, which includes health law as one of its specialties, to draft and file the company's comments on a recently introduced legislative bill that if passed, would effectively legalize medical marijuana in that country and pave the way for expanded research. The Medical Innovation Bill was introduced in the legislature in February by terminally-ill IFP MP Mario Oriani-Ambrosini who stated in his introduction that, "...millions of people were going through the hell of being a cancer patient, and die and suffer, possibly unnecessarily, because government was not funding research and expediting approval for treatments where there was no profit to be made." Oriani-Ambrosini said tabling the bill to get the law changed was something he had to do. "This is my contribution to something that had to be done. I did not look for this fight... It found me." Under current South African legislation, medical practitioners are legally denied the right to prescribe certain proven effective and harmless medication to their patients, which includes cannabis, on the basis that there are insufficient legally required double blind clinical studies. However, such studies are often considered economically unviable as cannabis, a plant that is in the public domain, cannot be patented by big pharmaceutical companies. The bill's objectives are to establish one or more research hospitals where medical innovation can take place, especially with regard to the treatment and cure of cancer. The bill would also legalize the medical, industrial and commercial use of cannabis in South Africa in accordance with emerging world standards. Oriani-Ambrosini also pointed out the potential economic benefits of legalized cannabis in South Africa, including tax revenue and jobs in agriculture and industrial production. Commenting on the bill, Planda Vice President, Jamen Shively, stated, "As one of the few companies out there with a vested interest in medicinal cannabis research, and the stated goal of furthering such research, we see ourselves as duty-bound to help craft legislation and to support those institutions that are paving the way in this emerging field. The medical cannabis industry has been surviving solely on anecdotal evidence and limited medical research for too long. It is time to invest in legitimate, double blind human studies to confirm the effectiveness of cannabis therapy for not only cancers but also neural diseases such as Parkinson's, Alzheimer's, MS, PTSD and epilepsy. We applaud Mr. Oriani-Ambrosini for his pioneering legislation and look forward to doing our part in not only supporting his efforts but also funding research in South Africa if the bill eventually passes." www.stockwatch.com/News/Item.aspx?bid=U-et410210341-U%3aPLPL-20140311&symbol=PLPL®ion=U
|
|
|
|
Post by Hot Christian Stocks on Mar 12, 2014 8:35:11 GMT -5
$PLPL -states - Medical Innovation Bill was introduced in the legislature in Feb by terminally-ill IFP MP Mario Oriani-Ambrosini who stated in his introduction that, "...millions of people were going through the hell of being a cancer patient, and die and suffer, possibly unnecessarily, because government was not funding research and expediting approval for treatments where there was no profit to be made." www.stockwatch.com/News/Item.aspx?bid=U-et410210341-U%3aPLPL-20140311&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 13, 2014 7:10:53 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 14, 2014 8:42:11 GMT -5
Commenting on the mj bill, $PLPL Plandai Vice President, Jamen Shively, stated, "As one of the few companies out there with a vested interest in medicinal cannabis research, and the stated goal of furthering such research, we see ourselves as duty-bound to help craft legislation and to support those institutions that are paving the way in this emerging field. The medical cannabis industry has been surviving solely on anecdotal evidence and limited medical research for too long. It is time to invest in legitimate, double blind human studies to confirm the effectiveness of cannabis therapy for not only cancers but also neural diseases such as Parkinson's, Alzheimer's, MS, PTSD and epilepsy. We applaud Mr. Oriani-Ambrosini for his pioneering legislation and look forward to doing our part in not only supporting his efforts but also funding research in South Africa if the bill eventually passes." www.stockwatch.com/News/Item.aspx?bid=U-et410210341-U%3aPLPL-20140311&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 17, 2014 6:15:26 GMT -5
$PLPL - Plandai Vice President, Jamen Shively, stated, "As one of the few companies out there with a vested interest in medicinal cannabis research, and the stated goal of furthering such research, we see ourselves as duty-bound to help craft legislation and to support those institutions that are paving the way in this emerging field. The medical cannabis industry has been surviving solely on anecdotal evidence and limited medical research for too long. It is time to invest in legitimate, double blind human studies to confirm the effectiveness of cannabis therapy for not only cancers but also neural diseases such as Parkinson's, Alzheimer's, MS, PTSD and epilepsy. We applaud Mr. Oriani-Ambrosini for his pioneering legislation and look forward to doing our part in not only supporting his efforts but also funding research in South Africa if the bill eventually passes." www.stockwatch.com/News/Item.aspx?bid=U-et410210341-U%3aPLPL-20140311&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 18, 2014 7:08:57 GMT -5
$PLPL is one of the few cannabis OTC companies that is eagerly anticipating the legalization of medical marijuana nationwide. Currently the drug is legal medicinally in 20 states and Washington, D.C., but in this election year, that number is likely to grow. In each national election year, the frenzy begins again and with it, a growing momentum that has the U.S. drawing closer to a nationwide acceptance www.stockwatch.com/News/Item.aspx?bid=U-i1095827-U%3aPLPL-20140306&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 18, 2014 10:48:23 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 19, 2014 8:40:26 GMT -5
$PLPL Video of the test Stage 1 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa youtu.be/l8kQqF_dJFQ |
|
|
|
Post by Hot Christian Stocks on Mar 20, 2014 8:31:58 GMT -5
$PLPL Announces Favorable Results for Human Clinical Trial 2014-03-20 09:18 ET SEATTLE, WA(eTeligis.com)Planda Biotechnology, Inc. (OTCQB:PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced favorable results from a recent human clinical trial involving a topical preparation of its Phytofare Catechin Complex. The study, which was undertaken by Prof. Banie Boneschans, North West University in Potchefstroom, South Africa, one of the leading research universities on the continent, was a double-blind study that tested the anti-aging properties of Phytofare. Specifically, the trial tested surface parameters (scaling and roughness), skin hydration, and skin elasticity. The results, which were released to the company on March 17, stated that Phytofare yielded "statistically significant" results when compared to a baseline product.The trial involved 35 female Caucasian test subjects who applied two topical creams daily, the only difference being that one contained Phytofare, to skin patches which were tested at 14, 28, and 42 days. The process of aging has a direct impact on the status of the skin surface. Skin imperfections, such as wrinkles and scaliness, reflect light differently than smooth, younger skin. A UVA-light camera with a black-and-white video sensor was used to photograph the skin surface and then measured the differences in texture. The study showed that the addition of Phytofare improved skin roughness by as much as 15% at 28 days, and a reduction in scaliness of the stratum corneum by 20%.Both of these measures were deemed "statistically significant" by the researcher. In testing skin hydration, a Corneometer(R) was used to measure the change in the dielectric constant due to skin surface hydration.The study showed the Phytofare increased skin hydration by 15% at both 28 and 42 days, compared to .9% and 7.8% for the base product.The study pointed out that skin hydration improved significantly at 28 days and then maintained that level throughout the study. The elastic properties reflect the skin's ability to return to its initial position after deformation and can be effected by chronological- and photo aging of the skin. Skin elasticity was evaluated by means of a Cutometer(R).The study showed an average improvement in skin elasticity of 1% at 42 days, though there was significant inter subject variation which rendered the results inconclusive with a recommendation for a larger sample size and longer duration for a future study. Planda Vice President Jamen Shively commented, "This study validates the last decade of research and illustrate the benefits of enhanced bioavailability.We envision our Phytofare topical formulation serving as the backbone for a host of potential cosmetic products and look forward to sharing the results with our distribution partners as we near release of Phytofare to the market." The company has placed an abstract of the study on its website:www.plandaibiotech.com www.stockwatch.com/News/Item.aspx?bid=U-et54567527-U%3aPLPL-20140320&symbol=PLPL®ion=U |
|
